{"a":[{"_":"ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms","$":{"href":"/manufacturing/itm-neuroendocrine-tumor-drug-spurned-fda-over-manufacturing-qualms","hreflang":"en"}}]}
RegulatoryrejectedNegative
AI Analysis
Summary
The FDA has rejected ITM Isotopes Technologies' lead pipeline drug candidate for neuroendocrine tumors due to manufacturing concerns.
Outcome Details
FDA denied lead pipeline candidate due to manufacturing qualms
Importance:8/10
Sentiment:
-0.90
FDA rejectionManufacturingNeuroendocrine tumorRare disease
Read the original article
Published by FierceBiotech on August 10, 2026 11:09 AM